Call the coronavirus hotline with your questions at 1-833-4-ASK-ODH

Johnson & Johnson to Spend up to $200M on Ebola Vaccine Program

Archives
5315048_G_531504871

NEW BRUNSWICK, N.J. (AP) – Johnson & Johnson will start safety testing in early January on a vaccine combination that could protect people from a strain of the deadly Ebola virus.

The health care products maker said it has committed up to $200 million to speed up and expand production of a vaccine program being developed by its Janssen Pharmaceutical Companies.

J&J is developing the vaccine with the Danish biotech company Bavarian Nordic. It involves a regimen in which two vaccines are delivered two months apart. The combination provided complete protection in animals against a virus strain similar to the one causing the current outbreak in West Africa that has killed thousands of people.

The New Brunswick, New Jersey, company said it will also determine whether its vaccine protects against the version causing the outbreak.

(Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)

Copyright 2020 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

video

More Video

Ohio Lottery

Don't Miss

Trending Stories

More Top News

WTRF 7News Twitter